Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown benefit in adolescents with obesity and type 2 diabetes, improving both weight and lipid profiles [26, 27]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.